# VisusNano

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/visusnano

- Industry: Medical Devices & Equipment
- Headquarters: London, UK
- Website: www.visusnano.com
- Latest round: Seed (Oct 2, 2018)
- Investors on record: 1

## About

VisusNano Ltd. is focused on pioneering advanced drug-eluting intraocular lens implants that enhance surgical outcomes for cataract patients. Their innovative solutions aim to mitigate postoperative complications and improve patient adherence to treatment regimens.VisusNano Ltd., established in 2016, specializes in developing drug-eluting intraocular lens technology. Headquartered in London, UK, the company has experienced strategic pivots, indicating growth and adaptability. Founded by Darren Pitt, Elodie Siney, Joanna Gould, and Philip Alexander, Joanna Gould currently serves as CEO. The company has engaged in 2 funding rounds, with the most recent Seed funding occurring on October 2, 2018, from returning investor SOSV. Financial terms of the deal were not disclosed.VisusNano Ltd. specializes in the development of innovative drug-eluting intraocular lens implants designed for patients undergoing cataract surgery. Their core product offering revolves around a biodegradable polymer-based drug elution system integrated into the intraocular lens (IOL), enabling a slow and controlled release of therapeutic agents such as antibiotics, anti-inflammatories, and anti-proliferative agents. This technology addresses critical challenges associated with cataract surgery, including postoperative complications such as cell proliferation, intraocular infections, and inflammation that can lead to visual impairment.VisusNano Ltd. generates revenue through partnerships with healthcare providers and veterinary clinics that utilize their drug-eluting IOL technology. The transactions typically involve direct sales of the IOL products to hospitals and surgical centers performing cataract surgeries. Each sale is likely accompanied by a value-added service, such as training for medical professionals on the implantation and benefits of the drug-eluting technology. The EBITDA for the most recent year, 2022, was 0.VisusNano Ltd. is actively working on expanding its product line, with plans to introduce new drug-eluting lenses tailored for specific patient needs by 2025. The company aims to penetrate additional markets in Europe and North America within the next three years. The Seed funding raised in October 2018 will support research and development initiatives to enhance their product offerings and facilitate market entry strategies.

## Funding rounds

- Seed, Oct 2, 2018 — SOSV
- Seed, Dec 22, 2017 — SOSV

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed